Intellia Therapeutics (NTLA) Free Cash Flow (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Free Cash Flow data on file, last reported at -$117.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 21.25% year-over-year to -$117.3 million in Q1 2026; TTM through Mar 2026 was -$364.2 million, a 2.96% increase from a year earlier, with the FY2025 full-year figure at -$395.9 million, down 13.28% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$117.3 million, down from -$69.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for NTLA reached as high as -$56.3 million in Q2 2024 and fell as low as -$149.0 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$93.7 million across 5 years, with a median of -$85.4 million in 2024.
• Across the five-year window, Free Cash Flow soared 40.68% in 2024 and sank 76.77% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$89.3 million in 2022, then increased by 8.06% to -$82.1 million in 2023, then slipped by 4.0% to -$85.4 million in 2024, then rose by 18.72% to -$69.4 million in 2025, then plunged by 69.06% to -$117.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$117.3 million in Q1 2026, -$69.4 million in Q4 2025, and -$77.9 million in Q3 2025.